Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma

被引：5

作者：

Sun Fu-kang ^{[1
]}

He Hong-chao ^{[1
]}

Su Ting-wei ^{[2
]}

Zhou Wen-long ^{[1
]}

Huang Xin ^{[1
]}

Dai Jun ^{[1
]}

Shen Zhou-jun ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Urol, Shanghai 200025, Peoples R China

[2] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Endocrinol,Clin Ctr Shanghai Endocrine & Met, Shanghai 200025, Peoples R China

来源：

CHINESE MEDICAL JOURNAL | 2012年 / 125卷 / 12期

关键词：

sunitinib; targeted therapy; anti-angiogenesis; malignant pheochromocytoma; EFFICACY;

D O I：

10.3760/cma.j.issn.0366-6999.2012.12.027

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sporadic malignant pheochromocytoma, a rare disease with poor prognosis, is always difficult to treat due in part to lack of effective agents. We presented three patients with advanced malignant pheochromocytoma treated by sunitinib, which indicates that sunitinib is an effective agent for this malignancy.

引用

页码：2231 / 2234

页数：4

共 50 条

[21] The novel multi-targeted receptor tyrosine kinase inhibitor MP470 inhibits synovial sarcoma proliferation in vitro
Combs, D.
Craniner, L. D.
Trevor, K. T.
JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (01) : 224 - 225
[22] ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
Jianbiao Zhou
Boon-Cher Goh
Daniel H Albert
Chien-Shing Chen
Journal of Hematology & Oncology, 2
[23] ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
Zhou, Jianbiao
Goh, Boon-Cher
Albert, Daniel H.
Chen, Chien-Shing
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2009, 2
[24] Contribution of Plasma Proteins, Albumin and Alpha 1-Acid Glycoprotein, to Pharmacokinetics of a Multi-targeted Receptor Tyrosine Kinase Inhibitor, Sunitinib, in Analbuminemic Rats
Toyama, Yukio
Ueyama, Jun
Nomura, Hiroshi
Tsukiyama, Ikuto
Saito, Hiroko
Hisada, Tatsuya
Matsuura, Katsuhiko
Hasegawa, Takaaki
ANTICANCER RESEARCH, 2014, 34 (05) : 2283 - 2289
[25] Interaction of the multi-targeted tyrosine kinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters
Hu, Shuiying
Chen, Zhaoyuan
Franke, Ryane
Zhao, Ming
Rudek, Michelle
Sparreboom, Alex
Baker, Sharyn
CANCER RESEARCH, 2009, 69
[26] CHIR258, a novel multi-targeted tyrosine kinase inhibitor, for the treatment of t(4;14) multiple myeloma.
Trudel, S
Li, ZH
Wei, E
Wiesmann, M
Rendahl, K
Moler, E
Chen, C
Reece, D
Mikhael, J
Heise, C
Stewart, AK
BLOOD, 2004, 104 (11) : 185A - 185A
[27] Phase I study of SU014813, a novel oral multi-targeted receptor tyrosine kinase (RTK) inhibitor.
Fiedler, W
Giaccone, G
Lasch, P
Van der Horst, I
Brega, NM
Gentile, A
Ljubimir, V
Pithavala, YK
Bokemeyer, C
Boven, E
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9061S - 9061S
[28] Effects of a multi-targeted receptor tyrosine kinase inhibitor on radiosentization of head and neck squamous cell carcinoma
Mirshahidi, Saied
Hsu, Heng-Wei
Chen, Chien-Shing
JOURNAL OF IMMUNOLOGY, 2012, 188
[29] E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
Hilary Glen
Susan Mason
Hitesh Patel
Kenneth Macleod
Valerie G Brunton
BMC Cancer, 11
[30] E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
Glen, Hilary
Mason, Susan
Patel, Hitesh
Macleod, Kenneth
Brunton, Valerie G.
BMC CANCER, 2011, 11

← 1 2 3 4 5 →